180 related articles for article (PubMed ID: 35343831)
1. Alternative Splicing: A New Therapeutic Target for Ovarian Cancer.
Yao S; Yuan C; Shi Y; Qi Y; Sridha R; Dai M; Cai H
Technol Cancer Res Treat; 2022; 21():15330338211067911. PubMed ID: 35343831
[No Abstract] [Full Text] [Related]
2. Systemic characterization of alternative splicing related to prognosis, immune infiltration, and drug sensitivity analysis in ovarian cancer.
Liu Q; Zhang H; Yang X; Liu X; Yin F; Guo P; Yin Y; Zheng K; Yang Z; Han Y
Ann Transl Med; 2022 Jan; 10(2):126. PubMed ID: 35282039
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis and establishment of a prediction model of alternative splicing events reveal the prognostic predictor and immune microenvironment signatures in triple negative breast cancer.
Yu S; Hu C; Liu L; Cai L; Du X; Yu Q; Lin F; Zhao J; Zhao Y; Zhang C; Liu X; Li W
J Transl Med; 2020 Jul; 18(1):286. PubMed ID: 32723333
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analysis of prognosis-related alternative splicing events in ovarian cancer.
Wang S; Wang S; Zhang X; Meng D; Xia Q; Xie S; Shen S; Yu B; Hu J; Liu H; Yan W
RNA Biol; 2022 Jan; 19(1):1007-1018. PubMed ID: 35980273
[TBL] [Abstract][Full Text] [Related]
5. Systematic Profiling of Alternative Splicing Events in Ovarian Cancer.
Liu J; Lv D; Wang X; Wang R; Li X
Front Oncol; 2021; 11():622805. PubMed ID: 33763357
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive characterization of the alternative splicing landscape in ovarian cancer reveals novel events associated with tumor-immune microenvironment.
Sun D; Zhao X; Yu Y; Li W; Gu P; Zhi Z; Xu D
Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35137909
[TBL] [Abstract][Full Text] [Related]
7. Genome-Wide Analysis of Prognostic Alternative Splicing Signature and Splicing Factors in Lung Adenocarcinoma.
Chang YS; Tu SJ; Chiang HS; Yen JC; Lee YT; Fang HY; Chang JG
Genes (Basel); 2020 Oct; 11(11):. PubMed ID: 33142748
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Analysis of Alternative Splicing Signature in Gastric Cancer Prognosis Based on The Cancer Genome Atlas (TCGA) and SpliceSeq Databases.
Cheng X; Li X; Gu Y; Zhou L; Tang J; Dai X; Jiang H; Huang Y; Zhang Y; Xu T; Liu Z; Zhao Q
Med Sci Monit; 2020 Nov; 26():e925772. PubMed ID: 33219199
[TBL] [Abstract][Full Text] [Related]
9. Systematic profiling of alternative splicing signature reveals prognostic predictor for ovarian cancer.
Zhu J; Chen Z; Yong L
Gynecol Oncol; 2018 Feb; 148(2):368-374. PubMed ID: 29191436
[TBL] [Abstract][Full Text] [Related]
10. Identification of Prognostic Alternative Splicing Signature in Breast Carcinoma.
Zhang D; Duan Y; Cun J; Yang Q
Front Genet; 2019; 10():278. PubMed ID: 30984247
[TBL] [Abstract][Full Text] [Related]
11. Identification of a glycolysis-related gene signature for survival prediction of ovarian cancer patients.
Zhang D; Li Y; Yang S; Wang M; Yao J; Zheng Y; Deng Y; Li N; Wei B; Wu Y; Zhai Z; Dai Z; Kang H
Cancer Med; 2021 Nov; 10(22):8222-8237. PubMed ID: 34609082
[TBL] [Abstract][Full Text] [Related]
12. Characterization of alternative splicing events and prognostic signatures in breast cancer.
Han P; Zhu J; Feng G; Wang Z; Ding Y
BMC Cancer; 2021 May; 21(1):587. PubMed ID: 34022836
[TBL] [Abstract][Full Text] [Related]
13. Systematic analysis and prediction model construction of alternative splicing events in hepatocellular carcinoma: a study on the basis of large-scale spliceseq data from The Cancer Genome Atlas.
Yang L; He Y; Zhang Z; Wang W
PeerJ; 2019; 7():e8245. PubMed ID: 31844595
[TBL] [Abstract][Full Text] [Related]
14. Identification of drug targets and prognosis projection for uterine carcinosarcoma based on alternative splicing events.
Zhang X; Yin X; Zhang L; Ye Z; Liang G
Comput Biol Med; 2023 Jan; 152():106346. PubMed ID: 36470146
[TBL] [Abstract][Full Text] [Related]
15. Systematic analysis of the relationship between ovarian cancer prognosis and alternative splicing.
Zhang D; Zou D; Deng Y; Yang L
J Ovarian Res; 2021 Sep; 14(1):120. PubMed ID: 34526089
[TBL] [Abstract][Full Text] [Related]
16. Alternative splicing acts as an independent prognosticator in ovarian carcinoma.
Ouyang Y; Xia K; Yang X; Zhang S; Wang L; Ren S; Zhou H; Liu Y; Tang F
Sci Rep; 2021 May; 11(1):10413. PubMed ID: 34001978
[TBL] [Abstract][Full Text] [Related]
17. Systematic analysis of alternative splicing signature unveils prognostic predictor for kidney renal clear cell carcinoma.
Song J; Liu YD; Su J; Yuan D; Sun F; Zhu J
J Cell Physiol; 2019 Dec; 234(12):22753-22764. PubMed ID: 31140607
[TBL] [Abstract][Full Text] [Related]
18. A prognosis-predictive nomogram of ovarian cancer with two immune-related genes:
Lin H; Wang J; Wen X; Wen Q; Huang S; Mai Z; Lu L; Liang X; Pan H; Li S; He Y; Ma H
Oncol Lett; 2020 Nov; 20(5):204. PubMed ID: 32963610
[TBL] [Abstract][Full Text] [Related]
19. Identification of a prognostic alternative splicing signature in oral squamous cell carcinoma.
Zhang S; Wu X; Diao P; Wang C; Wang D; Li S; Wang Y; Cheng J
J Cell Physiol; 2020 May; 235(5):4804-4813. PubMed ID: 31637730
[TBL] [Abstract][Full Text] [Related]
20. Chemoresistance-associated alternative splicing signatures in serous ovarian cancer.
Sun T; Yang Q
Oncol Lett; 2020 Jul; 20(1):420-430. PubMed ID: 32565967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
